Richard Curran: Trump may not want to close the stable door after the big US pharma horse has bolted
- Concerns rise over Australia's pharmaceutical exports, worth $1.1 billion, being affected by potential US tariffs, impacting the prices of essential medicines for Australians.
- Prime Minister Anthony Albanese stated that he ruled out retaliatory tariffs on the US, emphasizing Australia remains engaged diplomatically and that such tariffs would be paid by consumers.
- Health Minister Mark Butler announced new listings on the Pharmaceutical Benefits Scheme that will provide cheaper access to treatments for women, benefiting approximately 8,500 Australians annually, addressing criticisms about delays in adding new medications.
- Warnings have emerged that US companies might attempt to alter Australia's Pharmaceutical Benefits Scheme due to trade tensions.
16 Articles
16 Articles
Richard Curran: Trump may not want to close the stable door after the big US pharma horse has bolted
We may yet avoid a massive financial hit to the country through tariffs on US pharmaceutical exports, despite Donald Trump placing the sector front and centre at his meeting with the Taoiseach.
Canberra CityNews
The Canberra TimesUS tariffs should be a 'wake-up call' for Australia
The coalition wants the prime minister to negotiate directly with Donald Trump on tariffs. (Mick Tsikas/AAP PHOTOS) By Kat Wong in Canberra Australia is being urged to reconsider its relationship with the US after Donald Trump imposed hefty tariffs on all trading partners. The US president has flagged further trade measures, putting more pressure on the federal government after Australia failed to secure an exemption from his 25 per cent tariffs…
Fears Trump will hit vital Aussie industry
Fears have been raised that Australia’s billion dollar pharmaceutical export industry could be the next sector hit in US President Donald Trump’s tariff rampage, which could impact the prices of essential medicines for Aussies.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
